IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company based in New York, specializing in the development of monoclonal antibody therapies designed to treat autoimmune disorders. The company’s lead candidate, batoclimab, aims to target critical biological pathways associated with these diseases and is presently undergoing rigorous clinical trials to determine its efficacy and safety. With a robust pipeline and a commitment to addressing significant unmet medical needs in immunology, Immunovant offers an attractive opportunity for institutional investors looking to invest in the advancement of innovative biopharmaceutical solutions.